StockNews.com Upgrades CorMedix (NYSE:CRMD) to “Sell”

StockNews.com upgraded shares of CorMedix (NYSE:CRMDGet Rating) to a sell rating in a research report released on Thursday morning.

Shares of NYSE:CRMD opened at $4.96 on Thursday. CorMedix has a 12 month low of $3.65 and a 12 month high of $8.94.

About CorMedix (Get Rating)

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology.

Featured Articles

Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.